Key points are not available for this paper at this time.
The past decade has given us a better insight into the clinical uses and problems associated with glycated haemoglobin measurement. This article describes the recent studies that have helped clarify the role of glycated haemoglobin in the management of patients with diabetes. There remain numerous analytical problems associated with glycated haemoglobin measurement, such as the lack of assay standardisation and the problems related to its measurement in particular patient groups with haemoglobinopathies, fetal haemoglobin, renal failure (who form haemoglobin derivatives), and haemolytic diseases. These analytical problems have been reviewed recently1 and are
Eric S. Kilpatrick (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: